Abstract
The article presents the results of the study on the effectiveness and safety of sublingual allergen-specific immunotherapy in children at the age from 4 to 17 years old with spring polinosis and birch-pollen allergy syndrome, which were assessed using visual analogue and combination scales, provocative tests and the results of component resolved diagnosis.
Highlights
The article presents the results of the study on the effectiveness and safety
Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis
Pfaar O., Bachert C., Bufe A. et al Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases
Summary
Київ, Державна установа «Інститут педіатрії, акушерства та гінекології імені академіка О. М. Лук’янової НАМН України», відділення захворювань органів дихання та респіраторних алергозів у дітей, група проблем алергії та імунореабілітації дітей
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
